2025-09-22T10:06:53-04:00 2024-12-31 372123844 CASCADE CPA 421 WATER STREET 111 PRAIRIE DU SAC WI 53578 990 2024-01-01 871500208 WISCONSIN INSTITUTE FOR IMMUNE AND CELL THERAPY INC WISC 6087291450 726 POST ROAD MADISON WI 537134620 JEROME J JENDRISAK VP, SEC/TREAS. 6087291450 2025-09-19 true true JULIE MILLER P00388780 6086440206 2025-09-19 2024 2025-03-06 01:10:19Z WIICT GARY A DAHL 726 POST ROAD MADISON WI 53713 2050372 false X X 2021 WI THE ORGANIZATION'S PRIMARY EXEMPT PURPOSE IS TO ENGAGE IN THE CONTINUOUS ACTIVE CONDUCT OF MEDICAL RESEARCH IN CONJUNCTION WITH A HOSPITAL. 3 3 5 3 0 500000 2027000 124653 13755 8480 9617 0 633133 2050372 0 0 565229 341677 0 0 145915 63277 711144 404954 -78011 1645418 192955 1823568 30115 15310 162840 1808258 X THE ORGANIZATION'S PRIMARY EXEMPT PURPOSE IS TO ENGAGE IN THE CONTINUOUS ACTIVE CONDUCT OF MEDICAL RESEARCH IN CONJUNCTION WITH A HOSPITAL. false false 350818 13755 IN 2024, WIICT CONTINUOUSLY CONDUCTED RESEARCH ON AND PROVIDED 4 DIFFERENT MRNAS TO ITS COLLABORATORS AT NIH CLINICAL CANCER CENTER IN BETHESDA, MD FOR EVALUATION AND USE IN CLINICAL RESEARCH AND IN DIFFERENT PHASE 1 OR PHASE 1/2 HUMAN CLINICAL TRIALS. ONE OF THESE MRNAS ENCODES THE ACTIVE FORM OF A PROTEIN THAT IS INACTIVE OR LACKING IN ONE TYPE OF IMMUNE CELL OF PATIENTS HAVING A CERTAIN PRIMARY IMMUNODEFICIENCY (PID) DUE TO A MUTATION IN THE GENE THAT IS REQUIRED TO KILL MICROBIAL OR VIRAL PATHOGENS WITH WHICH THE PATIENT BECOMES INFECTED (ON AVERAGE EVERY 2-3 YRS). THIS TRIAL IS TESTING WHETHER PATIENTS CAN BE TREATED BY TRANSFECTING THE MRNA ENCODING THE ACTIVE PROTEIN INTO DEFECTIVE IMMUNE CELLS FROM THE PATIENT'S OWN BLOOD AND THEN REINTRODUCING THOSE TRANSFECTED CELLS INTO THE PATIENT. IN 2024, WIICT ALSO DESIGNED, MADE AND CONDUCTED RESEARCH ON THE YIELDS, PURITIES, ACTIVITIES, FUNCTIONS AND PROPERTIES OF MULTIPLE DIFFERENT BASE EDITING ENZYMES, GENE EDITING ENZYMES, AND BXB1 RECOMBINASE VARIANTS, WHICH MRNAS WERE PROVIDED TO OUR COLLABORATORS AND NIH, MASS GENERAL HOSPITAL AND ST JUDE'S CHILDREN'S HOSPITAL FOR THEIR EVALUATION AND RESEARCH RE ON- TARGET AND OFF-TARGET EDITING OF DIFFERENT GENES AND MUTATIONS IN HUMAN CELLS OR ANIMAL MODELS TO GENERATE DATA TO SUPPORT INDS FOR PHASE 1 OR PHASE 1/2 HUMAN CLINICAL TRIALS, INCLUDING BY USING DIFFERENT GUIDE RNAS AND OTHER CONDITIONS AND PARAMETERS TO ACHIEVE OPTIMAL EDITING OF SPECIFIC GENES AND MUTATIONS. 350818 true true false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false true false false false true 1 0 5 true false false false false false false false false false false false false false false X 3 3 true false false false false false false true true false false true true true true false false false false false X GARY A DAHL 6087291450 726 POST ROAD MADISON WI 53713 X GARY A DAHL PRESIDENT 1.00 X X 0 0 0 JEROME J JENDRISAK VP, SEC/TREA 1.00 X X 0 0 0 KIERAN COE DIRECTOR 0.10 X 0 0 0 false false false 2027000 2027000 RESEARCH SERVICES AT COST 900999 13755 13755 13755 9617 9617 2050372 13755 9617 X 290760 290760 27721 27721 23196 23196 57572 8747 48825 243 243 3723 3723 OTHER CONSULTING SERVICES 1200 1200 BIOLOGICALS & CHEM R&D 394 394 BANK CHARGES 120 120 MISCELLANEOUS 15 15 10 10 404954 350818 54136 0 57713 52847 133359 1769786 1883 935 192955 1823568 30115 15310 30115 15310 X 65000 65000 97840 1743258 162840 1808258 192955 1823568 1645418 X false false false X NATIONAL INSTITUTES OF HEALTH CLINICAL CENTER BETHESDA MD RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED FORM 990, PAGE 2, PART III, LINE 4A IN 2024, WIICT CONTINUOUSLY CONDUCTED RESEARCH ON AND PROVIDED 4 DIFFERENT MRNAS TO ITS COLLABORATORS AT NIH CLINICAL CANCER CENTER IN BETHESDA, MD FOR EVALUATION AND USE IN CLINICAL RESEARCH AND IN DIFFERENT PHASE 1 OR PHASE 1/2 HUMAN CLINICAL TRIALS. ONE OF THESE MRNAS ENCODES THE ACTIVE FORM OF A PROTEIN THAT IS INACTIVE OR LACKING IN ONE TYPE OF IMMUNE CELL OF PATIENTS HAVING A CERTAIN PRIMARY IMMUNODEFICIENCY (PID) DUE TO A MUTATION IN THE GENE THAT IS REQUIRED TO KILL MICROBIAL OR VIRAL PATHOGENS WITH WHICH THE PATIENT BECOMES INFECTED (ON AVERAGE EVERY 2-3 YRS). THIS TRIAL IS TESTING WHETHER PATIENTS CAN BE TREATED BY TRANSFECTING THE MRNA ENCODING THE ACTIVE PROTEIN INTO DEFECTIVE IMMUNE CELLS FROM THE PATIENT'S OWN BLOOD AND THEN REINTRODUCING THOSE TRANSFECTED CELLS INTO THE PATIENT. IN 2024, WIICT ALSO DESIGNED, MADE AND CONDUCTED RESEARCH ON THE YIELDS, PURITIES, ACTIVITIES, FUNCTIONS AND PROPERTIES OF MULTIPLE DIFFERENT BASE EDITING ENZYMES, GENE EDITING ENZYMES, AND BXB1 RECOMBINASE VARIANTS, WHICH MRNAS WERE PROVIDED TO OUR COLLABORATORS AND NIH, MASS GENERAL HOSPITAL AND ST JUDE'S CHILDREN'S HOSPITAL FOR THEIR EVALUATION AND RESEARCH RE ON- TARGET AND OFF-TARGET EDITING OF DIFFERENT GENES AND MUTATIONS IN HUMAN CELLS OR ANIMAL MODELS TO GENERATE DATA TO SUPPORT INDS FOR PHASE 1 OR PHASE 1/2 HUMAN CLINICAL TRIALS, INCLUDING BY USING DIFFERENT GUIDE RNAS AND OTHER CONDITIONS AND PARAMETERS TO ACHIEVE OPTIMAL EDITING OF SPECIFIC GENES AND MUTATIONS. FORM 990, PAGE 6, PART VI, LINE 2 JERRY JENDRISAK GARY DAHL JOINTLY OWN OTHER BUSINESSES FORM 990, PAGE 6, PART VI, LINE 11B A COPY OF THE FORM 990 IS PROVIDED TO THE GOVERNING BODY PRIOR TO BEING FILED WITH THE INTERNAL REVENUE SERVICE FORM 990, PAGE 6, PART VI, LINE 12C THE ORGANIZATIONS WRITTEN CONFLICT OF INTEREST POLICY COVERS ANY "INTERESTED PERSON" COMPRISED OF ALL DIRECTORS OF THE BOARD OF DIRECTORS, OFFICERS, MEMBERS OF A COMMITTEE, OR STAFF MEMBERS OF THE ORGANIZATION. EVERY INTERESTED PERSON HAS A DUTY TO DISCLOSE POTENTIAL OR ACTUAL CONFLICT OF INTEREST EXISTS OCCUR AT ANY LEVEL WHERE THE PERSONAL, PROFESSIONAL, FINANCIAL INTEREST, OR FIDUCIARY DUTY OF THE INTERESTED PERSON IS OPPOSED TO THE ORGANIZATION, CONFLICTS WITH, OR INFLUENCES THE INTERESTED PERSON'S ACTIONS AND JUDGEMENT. THE BOARD OF DIRECTORS OR AN APPLICABLE COMMITTEE DESIGNATED BY THE BOARD WILL REVIEW AND DETERMINE WHETHER A POTENTIAL OR ACTUAL CONFLICT OF INTEREST EXISTS WITH RESPECT TO EACH INTERESTED PERSON. THE INTERESTED PERSONS IN WHICH A CONFLICT OF INTEREST EXISTS WILL BE PROHIBITED FROM PARTICIPATING IN THE DELIBERATIONS UNLESS TO ANSWER QUETIONS, AND WILL NEVER BE PRESENT WHEN DECISIONS ON CONFLICT RELATED TO A TRANSACTION ARE MADE. FORM 990, PAGE 6, PART VI, LINE 19 THE ORGANIZATION DOES NOT MAKE ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC. FORM 990, PART IX, LINE 11G PAYROLL FEES 5,690 0 0 401K ADMIN FEES 3,057 0 0 CONCTRACTOR CONSULTING FEES 0 48,825 0 TOTAL 8,747 48,825 0 WISCOTX HOLDINGS LLC 726 POST ROAD MADISON WI 53713 465122681 HOLDING CO WI N/A false false CELLSCRIPT LLC 726 POST ROAD MADISON WI 53713 463213828 MANUFACTUR WI N/A C CORP false false false true false false false false false false false false false false true false true true false false WISCOTX HOLDINGS LLC C 683000 CASH CELLSCRIPT LLC N N/A CELLSCRIPT LLC P 48825 COST/ALLOCATION AGREEMENT CELLSCRIPT LLC Q 13755 COST/ALLOCATION AGREEMENT SCHEDULE R PART V (2) CELLSCRIPT, LLC PROVIDES WISCONSIN INSTITUTE FOR IMMUNE AND CELL THERAPY, INC THE USE OF PORTIONS OF THEIR FACITLITY AT NO COST. PART III (D) WISCOTX HOLDINGS LLC WIICT IS NOT AN OWNER OF WISCOTX HOLDINGS, LLC OR CELLSCRIPT, LLC AND THEREFORE HAS NO SHARE OF INCOME, ASSETS, OR PERENTAGE OWNERSHIP.